High-risk AML evidenced by a monoclonal antibody.
A monoclonal antibody has been raised against a surface membrane antigen present on leukemic myeloblasts. In 52 consecutive patients with acute myeloid leukemia treated in a standardized fashion with intensive chemotherapy the immunologic subclass with respect to this antigen was correlated to the clinical outcome. We found the expression of this antigen to predict a poor prognosis, when measured as survival of CR-patients and as survival after 1st relapse.
Avnstrøm
S
S
Finsen Institute, Department of Medicine, Gentofte Hospital, Copenhagen, Denmark.
Ralfkiaer
E
E
Hansen
N E
NE
Nissen
N I
NI
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D000954:Antigens, Surface / Q000032:analysis; D001752:Blast Crisis / Q000473:pathology; D001853:Bone Marrow / Q000473:pathology; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis
D000911:Antibodies, Monoclonal; D000954:Antigens, Surface